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Background: Bladder cancer (BC) predominantly affects the elderly and is often the cause of death among patients with muscle-
invasive disease. Clinicians lack quantitative estimates of competing mortality risks when considering treatments for BC. Our aim
was to determine the bladder cancer-specific mortality (CSM) rate and other-cause mortality (OCM) rate for patients with newly
diagnosed BC.
Methods: Patients (n¼ 3281) identified from a population-based cancer registry diagnosed between 1994 and 2009. Median
follow-up was 48.15 months (IQ range 18.1–98.7). Competing risk analysis was performed within patient groups and outcomes
compared using Gray’s test.
Results: At 5 years after diagnosis, 1246 (40%) patients were dead: 617 (19%) from BC and 629 (19%) from other causes. The 5-year
BC mortality rate varied between 1 and 59%, and OCM rate between 6 and 90%, depending primarily on the tumour type and
patient age. Cancer-specific mortality was highest in the oldest patient groups. Few elderly patients received radical treatment for
invasive cancer (52% vs 12% for patients o60 vs 480 years, respectively). Female patients with high-risk non-muscle-invasive BC
had worse CSM than equivalent males (Gray’s Po0.01).
Conclusion: Bladder CSM is highest among the elderly. Female patients with high-risk tumours are more likely to die of their
disease compared with male patients. Clinicians should consider offering more aggressive treatment interventions among older
patients.
Bladder cancer (BC) is the fourth most common male malignancy
worldwide with 297 300 new cases and 112 300 death in 2008
(Jemal et al, 2011). The majority of these tumours are urothelial
cell carcinomas (UCC), and clinical, pathological and molecular
data suggest two discrete disease phenotypes: low- and high-grade
disease (Catto et al, 2009). Most tumours arise following exposure
to either cigarette smoking or occupational carcinogens (Freedman
et al, 2011; Noon et al, 2012). Consequently, BC is most prevalent
in industrialised populations and many affected patients also suffer
from respiratory or cardiovascular disease, as well as other
malignancies. Carcinoma of the lung and bladder often coexist
owing to their shared aetiology (del Rey et al, 2010). Bladder cancer
is more common in older patients and this may affect cancer-
specific survival (Walters et al, 2009). Although BC has a higher
incidence in male patients, mortality is proportionally higher in
female patients (Mungan et al, 2000).
Patients and clinicians base treatment decisions on a variety of
factors: anticipated prognosis, a patient’s fitness for treatment and
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a patient’s likely life expectancy. Although various molecular,
histological and patient factors can be employed to predict clinical
outcomes (Youssef and Lotan, 2011), these tools usually do not
account for the competing mortality risk posed by other diseases.
For example, most analyses employ Kaplan–Meier methods to
predict survival. Unfortunately, this approach evaluates only one
outcome event: cancer-specific mortality (CSM), other-cause
mortality (OCM) or overall mortality. To assess survival where
mortality events compete, it is more appropriate to calculate a
cumulative incidence function (CIF). For this approach, censored
data are partitioned based on the probability of failure between the
two competing events (Scrucca et al, 2007).
Given the limited data available concerning competing mortality
in patients with BC (Messing et al, 2009), we analysed competing
mortality risks for patients with newly diagnosed UCC of the
bladder. We compared outcomes across patient populations to
obtain information to improve clinical decision-making.
MATERIALS AND METHODS
Patient and tumours. The Royal Hallamshire Hospital is the sole
urological provider for the city of Sheffield, UK (population
800 000). There is relatively little social mobility in this industrial
city; thus, patients with urological disease within this community
remain under the care of this department for the duration of their
care (Sheffield City Council, 2012). To determine the long-term
outcomes of patients with BC, we created a database of all patients
diagnosed with this disease at our institution between 1 January 1994
and 31 December 2009. We matched pathological features, hospital
billing data and death certification records (obtained from the Trent
Cancer Registry), as detailed elsewhere (Linton et al, 2012; Thomas
et al, 2013). We reviewed case-notes for patients with missing data
or conflicting codes and 2% of all cases (chosen at random).
To ensure data integrity, two workers separately merged data
streams to create parallel databases, which were then compared
and differences resolved by committee. Deaths were classified as
CSM or OCM according to the main attributable certified cause of
death (parts 1a or 1b on the UK death certificate; Rink et al, 2012)
and supported by selected case-notes (e.g. pathological or
radiological evidence of metastases/tumour progression, palliative
treatment before death).
Selection criteria. All adult patients with primary BC were
selected for inclusion (n¼ 3634). Those referred from other
institutions for secondary opinions, those with histology other
than UCC and those with inadequate follow-up (o6 months)
(n¼ 238) were excluded. We also excluded cases in which the
cause of death was unclear from the death certificate (e.g. renal
failure with coexisting BC) and not supported by post-mortem
evidence (n¼ 115).
Statistical analysis. Patients were stratified into four age groups
(o60, 60–69, 70–79 and 480 years) at diagnosis. Tumours were
assigned histological staging and grading according to the 1973
WHO and TNM classifications, and stratified according to
mortality risk: low-risk, non-muscle-invasive BC (MIBC) (grades
1 and 2, pTa), high-risk, non-MIBC (all high-grade, non-muscle-
invasive tumours, including any with CIS, and all tumours with
lamina propria invasion (pT1)) and MIBC (stage T2 or greater).
The Kruskal–Wallis analysis and w2 tests were used to compare
medians and proportions, respectively. Survival analyses with
respect to time were plotted using the Kaplan–Meier method.
Statistical tests were performed using SPSS (Vsn. 19.0; SPSS Inc.,
Chicago, IL, USA) or Prism (Vsn. 5.0; GraphPad Software, San
Diego, CA, USA). All statistical tests were two-tailed and
significance was defined as Po0.05. Competing risk analysis was
performed by calculating the CIF as described (Scrucca et al, 2007)
using R (Vsn. 1.43; The R Foundation for Statistical Computing;
Table 1. The patient cohort and follow-up data
Total cohort o60 years 60–69 years 70–79 years 80þ years P-value
No. of patients (%) 3281 (100) 487 (15) 850 (26) 1180 (36) 764 (23)
Sex
Male (%) 2368 (72) 336 (69) 640 (75) 870 (74) 522 (68) o0.01
Female (%) 913 (28) 151 (31) 210 (25) 310 (26) 242 (32)
Age
Median 72.6 54.7 65.8 74.9 83.8 o0.001
IQ Range 64.6–79.4 21.3–57.7 63.1–68.0 72.5–77.3 81.8–86.9
Tumour group
Low risk (%) 1440 (44) 242 (50) 367 (43) 519 (44) 312 (41) 0.03
High risk (%) 955 (29) 111 (23) 254 (30) 348 (30) 242 (32)
MIBC (%) 886 (27) 134 (28) 229 (27) 313 (27) 210 (27)
Follow-up (months)
Median 31.8 44.3 42.5 32.3 20.4 o0.001
IQ range 10.9–75.8 14.1–114.3 13.1–92.8 11.6–75.7 7.4–48.9
Status at 5 years
Alive (%) 1080 (33) 208 (43) 334 (39.3) 398 (34) 140 (18) o0.001
CSM (%) 617 (19) 55 (11) 134 (15.8) 226 (19) 202 (26)
OCM (%) 629 (19) 54 (11) 104 (12.2) 238 (20) 233 (31)
Censored (%) 955 (29) 170 (35) 278 (32.7) 318 (27) 189 (25)
Abbreviations: CSM¼ cancer-specific mortality; MIBC¼muscle invasive bladder cancer; OCM¼other-cause mortality.
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http://www.R-project.org). Comparison of specific CIFs was
performed using Gray’s test (Gray, 1988). Competing mortality
data models were plotted using a smoothed nonlinear fit to the
events in Prism.
RESULTS
Patients and survival. We identified 3281 patients suitable for
analysis (Table 1). The cohort comprised 2368 (72%) male and 913
(28%) female patients. The median age at presentation was 72.6
years (IQ range 64.6–79.5). Muscle-invasive tumours were present
in 886 (27%) and high-risk tumours in 955 (29%) patients at
diagnosis. The tumour phenotypes changed with age. While low-
risk tumours were more common in younger patients (50% and
41% of tumours in the youngest and oldest cohorts, respectively),
high-risk tumours increased with age (23% vs 32%, respectively,
P¼ 0.03). The median follow-up for the population was 48.2
months (IQ range 18.1–98.7) and decreased with rising age
(Po0.001). For patients who survived 5 years (n¼ 1080), the
median follow-up was 100.4 months (IQ range 76.9–134.6). At 10
years, 372 patients were alive, 665 had died of BC and 895 had died
of another cause. Outcome analyses evaluated the cumulative
survival from diagnosis of the entire cohort with respect to all-
cause mortality (ACM) and CSM (Figure 1). In general, ACM
increased progressively as patients aged, in contrast to CSM in
which most BC deaths occurred within 3 years of diagnosis.
Competing risks. To evaluate 5-year OCM and CSM, cumulative
incidence curves were generated for the cohort and stratified
according to age at diagnosis and tumour risk. The summary data
is provided in Table 2 and presented in Figure 2. Estimated CSM
varied from 0.9% (95% CI: 0.2–3.1) to 59.3% (95% CI: 51.4–66.4)
and estimated OCM from 5.0% (95% CI: 2.4–8.9) to 43.8% (95%
CI: 37.3–50.1), depending on the patient age and tumour type. As
expected, CSM increased proportionally with tumour risk (5.4% vs
24.4% vs 49.7%, for low-risk, high-risk and muscle-invasive disease,
respectively, Po0.001). In contrast, OCM did not vary with
tumour risk for the majority of patients (i.e. those aged 60–79 years
(62% of the population)).
Outcomes with respect to patient age. Comparisons across
patients harbouring the three tumour subgroups revealed that
CSM increased directly with age (Gray’s, Po0.001). This was also
true for OCM, except for patients with MIBC. While the findings
of higher OCM with age were expected, we were surprised that
CSM was so strongly associated with age. To investigate possible
explanations for this finding, we compared treatments adminis-
tered to patients in the high-risk and MIBC cohorts. As reported
previously (Thomas et al, 2012), intravesical BCG for high-risk
disease was used less frequently in the oldest patients (administered
to 38% of patients aged o60 years, 36% for patients aged 60–69
years, 37% for patients aged 70–79 years and 31% for those aged
480years, trend not significant). Older patients were also less
likely to undergo transurethral re-resection of the bladder within 3
months of initial resection (diagnosis) (31% for patients agedo60
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Figure 1. All-cause mortality (top) and disease-specific mortality
(bottom) are plotted using the Kaplan–Meier method. The number
remaining at risk is shown below the time intervals.
Table 2. Estimated 5-year CSM and OCM for the 12 patient groups
Age
group Tumour group
P-value
Low risk High risk MIBC
o60 years
CSM
(95% CI)
0.9 (0.2–3.1) 11.6 (6.1–19.1) 41.0 (31.1–50.7) o0.001
OCM
(95% CI)
5 (2.4–8.9) 13.2 (7.1–21.1) 30.6 (21.9–39.8) o0.001
60–69 years
CSM
(95% CI)
3.6 (1.9–6.2) 17.2 (12.3–22.8) 48.1 (40.3–55.5) o0.001
OCM
(95% CI)
12.7 (9.1–16.8) 15.5 (10.8–20.9) 20.5 (14.7–27.1) ¼0.41
70–79 years
CSM
(95% CI)
6.8 (4.6–9.5) 24.3 (19.5–29.4) 48.3 (42.0–54.4) o0.001
OCM
(95% CI)
21.5 (17.7–25.7) 24.8 (19.9–30.0) 30.2 (22.5–36.1) ¼0.77
80þ
CSM
(95% CI)
8.4 (5.4–12.2) 37.7 (30.9–44.5) 59.3 (51.4–66.4) o0.001
OCM 43.8 (37.3–50.1) 38.2 (31.3–45.1) 30.8 (23.7–38.2) o0.001
P CSM o0.001 o0.001 o0.001
P OCM o0.001 o0.001 ¼ 0.152
Abbreviations: CI¼ confidence interval; CSM¼ cancer-specific mortality; OCM¼other-
cause mortality.
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years, 27% for patients aged 60–69 years, 24% for patients aged
70–79 years and in 19% of those aged 480 years, trend not
significant). For patients with MIBC, radical cystectomy or radical
radiotherapy was used in 52% of patient’s aged o60 years, 50%
aged 60–69 years, 34% aged 70–79 years and in only 12% of those
aged 480 years (w2 Po0.001; Supplementary Table 1).
Patient age did not explain changes in CSM for patients with
low-risk BC. To understand this finding, we reviewed the
frequency of grade 1 disease by age cohort. We found that grade
1 (well-differentiated) tumours comprised 152 of 242 (63%), 193 of
366 (53%), 259 of 519 (50%) and 176 of 312 (44%) of low-risk
cancers for patients aged o60, 60–69, 70–79 and 480 years,
respectively. Therefore, the proportion of grade 2 tumours
increased with age, rising from 37 to 56% through the four age
groups. Older patients appear to present with increasingly high-
grade disease (w2 Po0.001).
Outcomes for male and female patients. Data suggest worse
outcomes for female patients with BC when compared with male
patients (Mungan et al, 2000). This may be due to more aggressive
tumours at presentation or the higher average age achieved by
female patients. To investigate this finding, we analysed the
cumulative incidences of OCM and CSM with respect to gender
(Figure 3). At 5 years, there were no significant differences in the
estimated male and female OCM and CSM for patients with low-
risk or MIBC disease. For patients with high-risk tumours, there
was no difference in estimated OCM between male and female
patients, but female patients were more likely to die from BC than
male patients (CSM¼ 32% vs 22%, respectively, Gray’s Po0.01).
Male and female patients with high-risk disease were equally likely
to receive BCG therapy (male 36% vs female 32% (P¼ 0.4)).
Diagnoses of non-CSM. We tabulated the specific diseases
responsible for OCM to understand the non-BC deaths in our
cohort (Table 3). Other diseases, such as pulmonary and cardiac,
accounted for the majority of deaths (470 of 629 (75%)). Analysis
by age and tumour group (Supplementary Table 2) showed that the
youngest patients with MIBC had more deaths due to other
malignancies (n¼ 19) when compared to their peers with low- and
high-risk disease (n¼ 4 and 6 respectively, (w2 Po0.001).
DISCUSSION
To date, this is the largest report regarding competing mortality in
patients diagnosed with the spectrum of BC. We found that
outcomes for patients with newly diagnosed BC vary between
excellent for young patients with low-risk disease (95% survival at
5 years) to extremely poor for older patients with muscle-invasive
disease (10% survival at 5 years). CSM increased with advancing
stage and worsening cellular differentiation. Cancer-specific
mortality was highest in older patients because older patients
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Figure 2. The 5-year competing mortality data models for patients stratified by primary tumour (columns) and age at diagnosis (rows). Black shaded
area¼estimated CSM (eCSM) and grey shaded area¼ estimated OCM (eOCM) – plotted as 1 minus the sum of CSM and OCM.
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had a higher prevalence of high-risk tumours and were less likely
to undergo radical curative treatment (Nielsen et al, 2007) or
receive intravesical therapies when compared with younger
patients. While out data support this association, we could not
exclude disease-related factors (such that older patients develop
more aggressive cancers). In contrast, OCM did not vary with
tumour type for the majority of patients (i.e. the 62% aged between
60 and 79 years). Among older patients where CSM was highest,
OCM was lowest. Among younger patients, OCM increased with
worsening tumour type. Patients with advanced tumours were
more likely to die of a competing mortality when compared to
patients with low-risk cancers. As this finding appeared counter-
intuitive, we examined specific causes of OCM within these
populations. As shown in Table 3, younger patients with MIBC
were more likely to die of other malignancies when compared to
those with low-risk cancers. Possible explanations include higher
carcinogen exposures(Sturgeon et al, 1994) necessary for invasive
carcinogenesis in young patients, treatment-related mortality (e.g.
post-radical therapy) or the misclassification of the certified cause
of death.
Our finding that female patients with high-risk disease have a
higher CSM than their male counterparts is novel and will need
further investigation. We believe that the observation is real, given
that we evaluated 212 female patients and 743 male patients with
this disease. Palou et al (2012) in a retrospective analysis of 146
patients with primary stage T1G3 NMIBC treated with BCG found
female gender to be a poor prognostic factor for CSM. As no
gender difference in CSM was noted in the invasive BC cohort (the
published literature contains conflicting reports on gender
differences following cystectomy; Mungan et al, 2000; Youssef
and Lotan, 2011; Otto et al, 2012), it is interesting to speculate
about the causes of our specific observation among patients with
high-risk disease. Potential explanations include that: (1) female
patients respond less well to BCG immunotherapy than male
patients (as suggested by Palou et al, 2012), (2) female bladders
maybe less well staged at resection (female bladders are typically
thinner walled than obstructed male bladders and so more prone to
understaging muscle-invasive disease) or (3) there are longer
delays in the time to diagnosis for female patients (as irritative
bladder symptoms or haematuria in female patients are initially
treated as infections or detrusor over activity, before further
investigation) (Johnson et al, 2008).
Our data complement and enhance the few previous manu-
scripts reporting competing mortality in patients with UCC.
Messing et al (2009) quantified competing events in 509 male
patients diagnosed with BC in Wisconsin in 1988 according to
four age and three tumour cohorts.(Scrucca et al, 2007). We found
higher rates of OCM among patients with prostate cancers
and lower rates of CSM among the elderly and in men with
high-risk tumours. Given that overall mortality rates were similar
to the men in our series, these differences may reflect the
lack of female patients in the Wisconsin series or potential
misclassifications of the cause of death in some patients.
Lughezzani et al (2011) reported competing mortality in 11 260
patients following radical cystectomy using data from the
Surveillance, Epidemiology and End Results registries. In this
cohort of advanced tumours (89% were muscle invasive), CSM
dominated survival outcomes, so that OCM contributed to only
8–27% of deaths at 5 years. The highest rates of OCM were
seen in the oldest patients with the least invasive tumours (pT1 and
pT2). Inman et al (2009) reported competing mortality in 168
patients with UCC of the upper urinary tract. At a median of 6
years after surgery, around 1/3 of patients had died from
competing risks and around 40% from urothelial cancer. Tumour
stage and grade were the strongest predictors of the latter. Our
study did not stratify patients using existing comorbidity scores.
Mayr et al (2012) evaluated five different performance indices and
found all were associated with cancer-independent mortality, but
none with CSM.
Our study’s strength derives from its population-based study
design and the uniform management of affected patients by uro-
oncologists (Moore, 1995). Furthermore, the low migration rate
from this population ensures that a high proportion of patients
were followed to death or closure of data collection (Sheffield City
Council, 2012). Our data are representative of a Caucasian
Northern European population, and as such can be extrapolated
elsewhere into Northern Europe, North America and Australasia to
enhance clinical decision-making. Our study’s weakness results
primarily from the observational study design rather than
prospectively collected data. Another difficulty in interpreting
our data arises from the heterogeneity of treatment options, which
may have resulted in a biasing of the CSM (less fit patients may
have been declined this treatment).
This study allows clinicians to estimate and compare the risks of
CSM and OCM for patient with recently diagnosed bladder
carcinoma. We found that older patients had a significantly worse
cause-specific mortality than their younger colleagues despite
similar risks of OCM. Female patients have a higher risk of CSM
when compared with their male counterparts. While the former
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Figure 3. Estimated cumulative incidence curves for OCM and CSM as
competing events for male and female patients with (A) low-risk
tumours (n¼ 1027 males vs n¼413 females), (B) high-risk tumours
(n¼743 males vs n¼212 females) and (C) MIBC (n¼598 males vs
n¼288 females).
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may be due to more conservative treatment of aggressive BCs in
the elderly, the reasons for gender disparities remain unclear and
should be the subject of further research.
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